Long-acting cabotegravir significantly decreases incidence of HIV compared to daily oral tenofovir
1. Cabotegravir was shown to be superior to TDF-FTC in preventing HIV infection in women. 2. Both drugs were well ...
Tag: Cabotegravir
Oral HIV preexposure prophylaxis limits willingness to pay for long-acting injectable prophylaxis
1. Compared with generic oral emtricitabine-tenofovir disoproxil fumarate (F/TDF), long-acting injectable cabotegravir (CAB-LA) increased life expectancy by 28,000 QALYs. 2. ...
Cabotegravir plus rilpivirine given every 8 weeks is non-inferior to every 4 weeks for maintenance of HIV-1 viral suppression
1. At week 48, there was a similar proportion of participants with plasma HIV-1 RNA ≥ 50 copies per mL ...
